Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07130383). This is a study registration, not published results. Lead sponsor: Minghui Pharmaceutical (Hangzhou) Ltd. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 210 participants (ESTIMATED). Conditions: Advanced Breast Cancer, Advanced Malignant Solid Tumor. Interventions: DRUG: MHB036C for Injection; DRUG: MHB039A for Injection. Primary outcome measures: (Dose-Expansion Stage): Objective tumor response (ORR) determined by investigators according to RECIST v1.1 , Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years. Brief summary: This is an open-label, multicenter Phase II study of MHB036C combined with MHB039A in patients with advanced Breast Cancer or other advanced malignant solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MHB036C and MHB039A combination therapy.